Inclusion Criteria:  Diagnosis of  High grade glioma (WHO grade III or IV), histologically verified Diffuse Intrinsic Pontine Glioma, verified by radiologic criteria (magnetic resonance imaging (MRI)) or by histology. A biopsy is not required but recommended. Aged ≥ 12 months and < 18 years at the time of signing the informed consent Body weight ≥ 10 kg Lansky score (for patients < 16 years) or Karnofsky score (for patients ≥ 16 years) of ≥ 50 Reasonable life expectancy ≥ 8 weeks, as estimated by the treating physician Adequate hematological blood values and sufficient recovery from treatment-related toxicities (> grade 1) following previous anti-glioma treatments, as judged by the treating physician Written informed consent of parents or legal guardian. Written informed consent of patients aged 12 years or older (written informed consent of patients younger than 12 years is optional). Willing and able to comply with the protocol, as judged by the treating physician Female patients of child bearing potential must have a negative serum or urine pregnancy test at the time of screening. Female patients of child bearing potential and male patients must agree to use effective contraception before, during and for at least hundred days after the last study treatment administration. Female subjects who are breastfeeding should discontinue nursing prior to the first dose of study treatment and until at least hundred days after the last study treatment administration.  Exclusion Criteria:  Use of any investigational agents ≤ 4 weeks before the planned day of leukapheresis. Concomitant malignancy or history of another malignancy (unless the Investigator rationalizes otherwise) Known concomitant presence of any active immunosuppressive disease (e.g. HIV) or any active autoimmune condition, except for vitiligo Any pre-existing contra-indication for contrast-enhanced MRI Pregnant or breastfeeding Any other condition, either physical or psychological, or reasonable suspicion thereof on clinical or special investigation, which contraindicates the use of the vaccine, or may negatively affect patient compliance, or may place the patient at higher risk of potential treatment complications